title: Field evaluation of the efficacy and safety of emodepside/praziquantel spot-on solution against naturally acquired nematode and cestode infections in domestic cats.
abstract: Two controlled, blinded and randomized multi-site clinical field studies evaluated the efficacy and safety of emodepside/praziquantel spot-on in the treatment of gastrointestinal nematode and cestode infections in cats. In a study conducted in Europe, faecal egg count reductions of >98% for all nematode eggs and eggs of Toxocara cati, respectively, were observed in cats treated with emodepside/praziquantel spot-on (Profender, Bayer AG, Leverkusen, Germany). For a positive-control product containing selamectin (Stronghold) reductions of >95% were observed. A 100% reduction of faecal eggs and proglottids was observed in cats treated with emodepside/praziquantel spot-on that were infected with cestodes. In a study conducted in North America, cats were treated with either emodepside/praziquantel spot-on plus a placebo tablet or a combination of two control products containing, respectively, selamectin (Revolution) and epsiprantel (Cestex). Faecal egg count reduction for eggs of T. cati was >99% for both treatments. For faecal eggs and proglottids of Dipylidium caninum reductions of >99 and >97% were recorded for cats treated with emodepside/praziquantel spot-on and the control group, respectively. No adverse reactions were observed in the European study, and only mild ones of short duration in a few cats from both treatment groups of the North American study. The two studies demonstrated that emodepside/praziquantel spot-on is highly efficacious and safe under field conditions.
authors.affiliation: Bayer HealthCare AG, Animal Health Division, R&D Parasiticides, 51368, Leverkusen, Germany. gertraut.altreuther@bayerhealthcare.com.
authors.forename: G
authors.initials: G
authors.lastname: Altreuther
authors.affiliation: Bayer HealthCare LCC, Animal Health Division, Kansas, USA.
authors.forename: J
authors.initials: J
authors.lastname: Buch
authors.affiliation: Bayer HealthCare LCC, Animal Health Division, Kansas, USA.
authors.forename: S D
authors.initials: SD
authors.lastname: Charles
authors.affiliation: Bayer HealthCare LCC, Animal Health Division, Kansas, USA.
authors.forename: W L
authors.initials: WL
authors.lastname: Davis
authors.affiliation: Bayer HealthCare AG, Animal Health Division, R&D Parasiticides, 51368, Leverkusen, Germany.
authors.forename: K J
authors.initials: KJ
authors.lastname: Krieger
authors.affiliation: Klifovet AG, 80689, Munich, Germany.
authors.forename: I
authors.initials: I
authors.lastname: Radeloff
mesh_terms: D000287:Administration, Topical; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000469:parasitology; D002415:Cats; D002590:Cestode Infections / Q000188:drug therapy / Q000662:veterinary*; D047630:Depsipeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D009349:Nematode Infections / Q000188:drug therapy / Q000662:veterinary*; D011223:Praziquantel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D000871:Anthelmintics; D047630:Depsipeptides; D011223:Praziquantel; C468987:emodepside